• Idiopathic generalized epilepsy;
  • Epilepsy in adolescence;
  • Menarche;
  • Hormones;
  • Mesial temporal sclerosis;
  • Seizures


  1. Top of page
  2. Abstract

Summary: Specific epilepsy syndromes begin during adolescence and create a significant neurologic burden. Knowledge of these syndromes has important treatment and prognostic implications, which usually extend into adulthood. Little is known about the effect of menarche on seizures, even though a relationship of seizures to the menstrual cycle has been observed for many years. In general, puberty is not thought to influence seizure frequency. However, estrogen is thought to activate epileptiform activity; testosterone may decrease seizure activity; and progesterone decreases epileptiform discharges. These effects are mediated by effecting γaminobutyric acid (GABA) transmission. Idiopathic generalized epilepsies are the most frequent group with adolescent onset. These are probably polygenic in origin and represent a biologic continuum. Juvenile myoclonic epilepsy (JME) is the most common form. This contrasts with a variety of progressive myoclonic epilepsies that also are first seen in adolescence and have a genetic origin and specific treatments. Finally, although temporal lobe epilepsy associated with hippocampal sclerosis may have its origin in childhood, often the child does not come to surgical evaluation until adolescence or young adulthood. The characteristic clinical history, seizure semiology, and magnetic resonance imaging findings have allowed a discrete epilepsy syndrome to be established. Applying these same criteria to children and adolescents reveals that hippocampal sclerosis is the most common lesion responsible for their intractable temporal lobe epilepsy. Hippocampal sclerosis is probably underdiagnosed in children. The safety and efficacy of epilepsy surgery in the age group is excellent. Knowledge of the epilepsy syndromes that remit before adolescence, may persist into adolescence, or begin in adolescence is central to the treatment of this age group.

Epilepsy in adolescence is a significant neurologic burden with a prevalence of 1.5–2%. Specific childhood epilepsy syndromes may remit before adolescence (Table 1), whereas others may persist into (Table 2) or begin in adolescence (Table 3). Adolescence is a time of great change, with growth into adulthood, and preparation for employment, driving, relationships, and marriage. Epilepsy impinges on all of these areas. Knowledge of these syndromes has important treatment and prognostic implications.

Table 1.  Childhood-onset epilepsy syndromes that usually remit before or during adolescence
Benign childhood epilepsy with centrotemporal spikes
Benign childhood epilepsy with occipital paroxysms,  Panayiotopoulos type (early onset)
Childhood absence epilepsy
Acquired epileptic aphasia (Landau–Kleffner syndrome)
Table 2.  Childhood-onset epilepsy syndromes that may persist into adolescence
Benign childhood epilepsy with occipital paroxysms, Gastaut type  (late onset)
Benign myoclonic epilepsy in infancy
Lennox–Gastaut syndrome
Generalized epilepsy with febrile seizures plus
Childhood absence epilepsy
Epilepsy with myoclonic absences (Tassinari syndrome)
Eyelid myoclonia with absences (Jeavons syndrome)
Myoclonic astatic epilepsy of early childhood (Doose syndrome)
Table 3.  Epilepsy syndromes with onset in adolescence
Reading epilepsy
Photosensitive epilepsies
Juvenile absence epilepsy
Juvenile myoclonic epilepsy
Epilepsy with grand mal on awakening
Progressive myoclonic epilepsies
Mesial temporal lobe epilepsy
Nonepileptic seizures

We review the effect of menarche on epilepsy and epilepsy syndromes that begin in adolescence. The syndrome of mesial temporal lobe epilepsy is reviewed, realizing that it typically begins in childhood, but critical treatment decisions (i.e., surgical therapy) are often not approached or apparent until adolescence.


  1. Top of page
  2. Abstract

Hippocrates was the first to suspect an association between puberty and epilepsy (1). He thought that epilepsy had a more benign course during puberty and usually disappeared at that time. Subsequent physicians caring for adolescents with seizure disorders have noted an association between hormones and seizures.

In 1954, Penfield and Jasper (2) observed, “epileptic seizures in females often begin at the time of their menarche and some relationship to the menstrual cycle is a common observation, hence the term ‘menstrual epilepsy’ has been used to describe some cases.” In 1957, Bandler et al. (3) surveyed 30 women, and only four (13.3%) related seizures to the first menstrual period. If hormones increase the likelihood of seizure activity, then puberty alone should be a risk factor. However, in children with a diagnosis of epilepsy, an increased incidence of seizures has not been noted. Few studies have documented the effect of menarche on the incidence of seizures. In one retrospective study, 39 children (24 girls) with onset of epilepsy were followed up for 7 years, extending from prepuberty into puberty (4). A general trend toward fewer seizures during puberty was observed, but this reached significance only for the female patients after menarche. These changes could not be attributed to treatment. Rosciszewska (5) followed up 62 patients with previously diagnosed seizures (simple partial, complex partial, or generalized tonic–clonic) through menarche. One third had no change, one third had an increase, and one third had a decrease in seizure number. These studies concluded that despite hormonal changes, puberty does not influence seizure frequency. One study reported that the onset of seizures occurred within 3 years of menarche in 16 (64%) of 25 women in whom catamenial exacerbation of seizures developed (6).

Changes in EEG frequency and amplitude during the menstrual cycle have been noted, but the results have not been consistent (7). The driving response to photic stimulation is decreased during the preovulatory phase of the menstrual cycle, when blood estrogen levels are increasing (8). Estrogen potentiates the activity of norepinephrine, and it has been postulated that the decrease in EEG driving responses with estrogens is secondary to enhancement of the central adrenergic state. Therefore, driving response can be used as an indicator of adrenergic functioning within the central nervous system. Progesterone and testosterone may block or oppose the neurophysiologic effects of estrogen (7).

There is few data on the effect of sex steroids on the human EEG. An adolescent boy with posttraumatic epilepsy had EEG analysis performed before and then after treatment with testosterone, and after addition of clomiphene (9). There was no significant change in the number of sharp waves, but his seizures dramatically decreased. Spectral EEG analysis revealed decreased alpha, beta, and theta power values after testosterone treatment. Logothetis et al. (6) found that intravenous estrogen activated epileptiform activity in 11 (68.7%) of 16 patients. Additionally, 25% had a seizure in close temporal association. Conversely, Backstrom et al. (10) administered intravenous progesterone, sufficient to produce plasma concentrations achieved during the luteal phase, to seven women with partial epilepsy. Four (57%) of the seven showed a significant decrease in spike frequency during the infusion. In a single case study, administration of progesterone exacerbated absence seizures (11).

Animal models have been used to understand the interrelation between hormones and epilepsy in humans. The results have supported the clinical observations that steroid hormones can significantly affect seizure threshold and propagation (12,13). One of the first studies to address the effects of estrogens on the mammalian brain was performed in 1959 (14). Estrogen was given intravenously or applied directly to the cortex of rabbits. High-voltage spike discharges, clinical seizures, and status epilepticus occurred in two (40%) of 5 normal rabbits and five (62.5%) of 8 rabbits with brain lesions. Estrogen has been shown to increase the number of seizures in kainic acid, ethyl chloride, kindling, and pentylenetetrazol models (7,13,15) and to decrease the electroshock threshold in rats (7,16). Estrogen potentiates glutamate, blocks γ-aminobutyric acid (GABA)-mediated transmission, and increases the number of hippocampal CA1 dendritic spines and excitatory synapses (12).

The physiologic role of estradiol in influencing brain excitability was demonstrated by the finding that both male and female animals show the same intensity of seizure activity until the age of sexual maturation, when the female shows increased seizure susceptibility (17,18). Estradiol facilitation of seizure susceptibility appears to be due to induced changes in hippocampal circuitry, rather than to a generalized increase in neuronal excitability (19).

Studies on the effects of progesterone on seizure discharges in the experimental animal have been more variable and not so robust as those of estrogens (7). Progesterone has been shown to depress spontaneous interictal spikes, protect against pentylenetetrazol-induced seizures, and raise the seizure threshold in female but not male rats. Progesterone increased the number and total duration of spike–wave discharges in the WAG/Rij rat, a model for generalized epilepsy (20). Estradiol injections had no effect on the spontaneous spike–wave discharges. Injections of RU 38486, an antagonist of intracellular progesterone receptors, did not block the stimulatory effect of progesterone (20). This suggests that the effect of progesterone is not mediated through intracellular receptors. Progesterone is readily converted in the brain to highly neuroactive steroid metabolites, most notably allopregnanolone. These metabolites are capable of potentiating GABA transmission (12). It is possible that the epileptiform (i.e., in WAG/Rij rats) and antiepileptiform effects of progesterone are mediated through this metabolite. Progesterone also potentiates adenosine, a powerful endogenous inhibitor, and decreases the number of hippocampal CA1 dendritic spines and excitatory synapses.

Testosterone is capable of both a proconvulsant and an antiepileptic action, depending on the dose used, the animal age, and the seizure type (7). These inconsistent actions can be explained by the metabolism of testosterone. Testosterone is metabolized to estradiol, which can exacerbate seizures, and dihydrotestosterone, which inhibits N-methyl-d-aspartate (NMDA)-type glutamate transmission and may have antiseizure effects (12). Andostenediol, another metabolite, has a augmenting effect on GABA-mediated chloride transport. Using an aromatase inhibitor (i.e., testolactone ) along with testosterone blocks the metabolism to estradiol and may improve its antiepileptic effect (13).


  1. Top of page
  2. Abstract

A large proportion of all epilepsy composes the heterogeneous group of idiopathic generalized epilepsies (IGEs) (21). This is the most frequent group with adolescent seizure onset (22). IGEs are predominantly determined by genetic factors and are probably polygenic in origin. Recent genome mapping and positional cloning studies in affected families have identified several susceptibility genes for IGE (21).

Two or more different IGE phenotypes may be found in the same pedigree. Clinical and EEG overlap may be observed (Fig. 1)(22,23). Additionally, one IGE syndrome [i.e., juvenile myoclonic epilepsy (JME)] may evolve out of another typical IGE syndrome [i.e., childhood absence epilepsy (CAE)] after several years, when the patient reaches the manifestation age for the myoclonus (21,24). Based on such evidence, the concept of a biologic continuum has been proposed, with changes in the classification system (25). A similar IGE genotype may be present, but differing clinical symptoms (IGE syndrome) may depend on modifying genes or other factors (26). Supportive of this is recent documentation of a novel de novo mutation in one subject with CAE that evolved into JME (27). Animal studies demonstrate a dosage-sensitive gene function (haploinsufficiency) specific to brain, which may explain the mechanism of the IGE (28).


Figure 1. Idiopathic generalized epilepsy: age at onset. GTC, generalized tonic–clonic; JME, juvenile myoclonic epilepsy; CAE, childhood absence epilepsy; JAE, juvenile absence epilepsy.

Download figure to PowerPoint

Juvenile myoclonic epilepsy

JME is a common form of IGE, having an overall prevalence of 5–10%(29). Individuals present between the ages of 8 and 26 years, but in >75%, initial manifestations occur between ages 12 and 18 years. Early morning myoclonus, primarily involving both upper extremities, precipitated by sleep deprivation, fatigue, or alcohol, is characteristic at onset (30–33). Generalized tonic–clonic (GTC) seizures occur in >90%, and 30% have absence seizures. The GTC seizures are often preceded by a series of myoclonic jerks (31). When absence seizures occur, they are often infrequent. Studies from independent groups have provided evidence for the existence of a JME locus on chromosome 6p (designated EJM1) (21,34–36). This expresses the phenotype of classic JME. A separate susceptibility locus for JME maps to chromosome 15q14 (37). CAE that evolves to JME has a locus on chromosome 1p (21).

The EEG background is typically normal. The characteristic interictal EEG findings are generalized 4- to 6-Hz polyspike and slow-wave complexes; however, many patients have 3- to 4-Hz spike and slow-wave complexes. Photosensitivity is seen in about one third of patients; however, the yield may be increased by extending intermittent photic stimulation for ≤5 min (38). Documentation of photosensitivity has important management implications. Fewer than 10% of patients persistently have normal EEG findings (29). Asymmetric EEG findings, including lateralized sharp waves, unilateral spike, or polyspike and slow-wave complexes, or voltage asymmetries have been reported in 38% of patients (29). In most cases, they shifted between the hemispheres on consecutive EEG recordings. Occurrence of lateralized or persistently focal EEG abnormalities can occur (29,39,40). This may result in misdiagnosis or a delay in JME diagnosis. Sleep EEGs had the highest diagnostic yield, with some authors reporting abnormalities in 100% of cases (30). Epileptiform discharge rates on sleep EEGs typically increased significantly during the transition phase (i.e., the asleep-to-awakening state). More than half of patients may show normalization of the EEG after drug therapy (41).

The characteristic ictal EEG for a myoclonic jerk in JME is a bilaterally symmetrical, frontocentrally accentuated, generalized polyspike-and-wave complex. The spikes usually have a frequency of 10–16 Hz, and the slow waves have a frequency of 2–5 Hz (32).

Rarely, structural brain lesions may be found, but these do not appear to influence the therapeutic response or prognosis in JME (42). A single case of JME has been reported in a man with mental retardation and structural brain changes presumed secondary to acquired perinatal damage (43). Voxel-based analysis of magnetic resonance imaging (MRI) has revealed an increase in cortical gray matter (especially mesial frontal lobes) in 40% of patients with JME (39).

JME may be mimicked by nonepileptic seizures, but this is a rare semiology for nonepileptic seizures (44).

Epilepsy with grand mal on awakening

Epilepsy with grand mal on awakening (GMA) is a syndrome of IGE characterized by GTC seizures occurring predominantly or exclusively shortly after awakening (without respect to the time of day) or in the evening with relaxation (45,46). The age at onset is broader than the other IGEs, but a clear peak occurs around puberty. A genetic predisposition is hypothesized. Other seizure types, absence or myoclonic, may occur, and a series may precede the GTC seizure. This clinical phenomenon is observed in JME, suggesting an overlap between the two syndromes in some patients. Recent linkage studies have suggested that JME and GMA could be different clinical forms of the same genetic condition (26). Seizures are easily precipitated by sleep withdrawal and excessive alcohol intake. The EEG shows a normal background with generalized epileptiform discharges (irregular, spike, or polyspike and wave complexes at 2.5–4 Hz) and photosensitivity in 13–17%.

Juvenile absence epilepsy

Juvenile absence epilepsy (JAE) is an infrequent IGE with onset in adolescence (47). There probably exists an overlap between this and JME (22). This occurs in predominantly neurologically normal patients, with no sex preference. The absence seizure frequency is less than in CAE, with absences occurring sporadically. The majority of patients also have GTC seizures. When GTC seizures accompany, they mostly occur on awakening. The similarities between JAE and GMA support the concept of a neurobiologic continuum for IGE (48). JAE appears to be an intermediate syndrome between CAE and JME.

The EEG background is usually normal. The characteristic feature of the interictal and ictal EEG is a generalized, regular, spike-and-wave complex at 3.5–4 Hz, maximally over the frontal head regions. This can be precipitated by hyperventilation, sleep deprivation, and infrequently by photic stimulation.

Progressive myoclonic epilepsies

Progressive myoclonic epilepsies are rare, accounting for only 1% of all epilepsy cases in childhood and adolescence (49,50). A PME syndrome is characterized by the association of (a) a myoclonus syndrome involving massive myoclonus and asymmetric myoclonus, (b) generalized tonic–clonic seizures, (c) mental deterioration resulting in dementia, and (d) a neurologic syndrome with cerebellar manifestations (51). A large number of causes for the PME have been identified, many with specific genetic etiologies that can now be identified. Some PME disorders, with special emphasis on the recent molecular genetics discoveries and EEG aspects, are reviewed. Overall, the EEG typically shows a slowing of the background rhythm, generalized epileptiform discharges (Fig. 2), and photosensitivity (51). Giant cortical responses are often observed with somatosensory evoked potentials (SSEPs; Fig. 3) (51).


Figure 2. Progressive myoclonic epilepsy with generalized, irregular polyspike or spike and slow-wave complexes seen in sleep.

Download figure to PowerPoint


Figure 3. Somatosensory evoked potentials of the left median nerve in an adolescent with Lafora body disease. Note the giant cortical response (N20-P22 amplitude = 14.89 μV).

Download figure to PowerPoint

Unverricht–Lundborg disease (Baltic myoclonus, locus symbol EPM1) is an autosomal recessive disorder, which occurs in the Finnish population with an incidence of one in 20,000. Stimulus-sensitive myoclonus begins between ages 6 and 15 years, and then mild mental retardation, ataxia, and dysarthria slowly develop. Unverricht–Lundborg disease was mapped to chromosome 21q 22.3, and the EPM1 gene was shown to encode cystatin B (34). Cystatin B, a member of a superfamily of cysteine protease inhibitors, is thought to inactivate proteases that leak out of the lysosome. Clinical and EEG photosensitivity are observed in ∼90% of patients. The EEG background is initially normal and slows over time. Irregular, generalized spike or polyspike and slow-wave complexes, maximal over the anterior head regions, are seen. In sleep, these epileptiform discharges may diminish in number.

Progressive myoclonus epilepsy with polyglucosan intracellular inclusion bodies (Lafora disease) is an autosomal recessive disorder localized to chromosome 6q-24 (34,52). The gene mutated in Lafora disease, EPM2A, encodes an intracellular protein tyrosine phosphatase, laforin. Periodic acid–Schiff-positive cytoplasmic inclusion bodies are present in neurons, heart, liver, and muscle. An axillary skin biopsy, which includes sweat gland ducts, reveals the characteristic inclusions. The onset occurs between 6 and 19 years. The initial seizures are often generalized tonic–clonic and associated with partial visual seizures involving scotomas or simple visual hallucinations. Soon after disease presentation, asymmetric myoclonic jerks occur, followed by dementia, ataxia, and visual loss. At presentation, the EEG may resemble an IGE, showing a normal background with isolated generalized spike and slow-wave discharges (Fig. 4). The EEG abnormalities often precede clinical symptoms. Photosensitivity is usually present (Fig. 5). The EEG quickly progresses to show background slowing, fast irregular generalized spike or polyspike and slow-wave discharges, and occipital spikes. The epileptiform discharges decrease during sleep. Initially, high-voltage somatosensory and visual-evoked potentials (VEPs) are recorded.


Figure 4. EEG performed in an 11-year-old girl with Lafora body disease after her first seizure. The semiology was consistent with an absence event. Note the brief generalized spike and slow wave burst seen interictally, resembling an idiopathic generalized epilepsy.

Download figure to PowerPoint


Figure 5. Adolescent with Lafora body disease. EEG during photic stimulation at 6 Hz shows marked photosensitivity and subsequent myoclonic jerks.

Download figure to PowerPoint

Mitochondrial genes are maternally inherited, and diseases due to mutations of mitochondrial DNA (mtDNA) include encephalopathies, myopathies, and multisystem disorders. Myoclonic epilepsy with ragged-red fibers (MERRF) is characterized by epilepsy, intention myoclonus, muscle weakness, progressive ataxia, and deafness. An A-to-G transition mutation at nucleotide pair 8344 in the pseudouridyl loop of the tRNAlys gene has been described in most families (34). The clinical phenotype varies depending on the amount and tissue distribution of mutant mtDNA in an individual. The age at onset varies greatly between childhood and the elderly. The EEG findings are an abnormally slow background, generalized irregular spike-and-wave, or polyspike-and-wave discharges, and occasional focal epileptiform discharges (53). Photosensitivity is uncommon, and when it occurs, the discharges show a posterior predominance. The normal elements of sleep are poorly differentiated, and in some patients, the generalized discharges are markedly attenuated.

The neuronal ceroid lipofuscinoses (NCLs) are characterized by the accumulation of abnormal amounts of lipopigments in lysosomes. Eight forms of NCL have now been identified on the basis of clinicopathologic, biochemical, and genetic testing (54–61). Two have onset during or near adolescence. All forms are autosomal recessive, except Kuf disease (CLN4), which also could be autosomal dominant. The juvenile form (JNCL or Batten–Spielmeyer–Vogt disease) begins between ages 4 and 10 years. This is the most common form in the United States. Most patients have visual failure and have the gradual development of dementia and extrapyramidal features, with seizures as a minor manifestation (54). The EEG background is initially normal, but then generalized slow activity appears. Generalized epileptiform discharges are often slow spike-and-wave complexes, typically activated by sleep. The electroretinogram (ERG) is flat, and VEPs are low amplitude or absent.

Adult NCL or Kuf disease typically begins between ages 11 and 55 years. Kuf differs from early-onset forms, in that visual symptoms are absent. Kuf disease occurs as a progressive myoclonic epilepsy or as a dementia with motor disturbances. The VEP is typically normal, in contrast to the abnormal VEP seen in childhood NCL. Giant cortical responses may be seen on SSEPs. The EEG findings are nonspecific, with initial generalized slowing of background activity and generalized epileptiform discharges (62). Photosensitivity may occur, but again it is rare, in contrast to the childhood forms in which it is common. Only tonic seizures may be observed.

Previously, diagnosis of NCL was based on age at onset and clinicopathologic findings. Recent phenotype/genotype analysis has been performed in large numbers of individuals with NCL (61,63). This has changed the diagnostic approach to NCL. Mutations in the CLN1 gene on chromosome 1p32 were associated with three different phenotypes: juvenile, infantile, and late infantile. Two common mutations account for 64% of the patients. Whereas a missense point mutation, 223A[RIGHTWARDS ARROW]C, was the most common among juvenile-onset forms, a nonsense point mutation, 451C[RIGHTWARDS ARROW]T, was the most common in infantile onset. All of the CLN1 probands were palmitoyl protein thioesterase (PPT) deficient and showed granular osmiophilic deposits (GRODs) at the electron microscopic (EM) level. Rarely the juvenile-onset form may be seen with mutation in the CLN2 gene on chromosome 11p15, and curvilinear bodies (CV) are seen on EM. All CLN2 probands had a deficiency of tripeptidyl-peptidase I (TTP I) activity. Typical juvenile NCL is due to a mutation of the CLN3 gene on chromosome 16p12.1. Fingerprint profiles (F) may be the only abnormality, or this may be seen with CV or GROD on EM. Adult NCL is due to a mutation of CLN4, and the chromosome location is unknown. The EM typically shows a mixture of F, CV, and GROD. The diagnosis of NCL is now based on clinicopathologic findings, ultrastructural studies, enzymatic assay, and molecular genetic testing. The recognition of variable onset from infancy to middle age supersedes the previous, traditional emphasis on age-related NCL forms.

Mesial temporal lobe epilepsy

Temporal lobe epilepsy associated with hippocampal sclerosis is the most common form of human epilepsy and represents a discrete syndrome that can be recognized in adolescence. Diagnosis of medically refractory MTLE before or during adolescence is important, because the seizures and their consequences can be eliminated by surgical therapy (anteromesial temporal lobectomy) in 80–90% of patients, and early surgical intervention provides the greatest opportunity for complete psychosocial rehabilitation. Recent volumetric MRI studies have suggested that hippocampal sclerosis is a progressive disorder with a risk for cognitive dysfunction (64). The characteristic clinical features and an ability to identify hippocampal disturbances noninvasively with modern MRI have allowed MTLE to be established as a discrete epileptic syndrome (65–69).

The clinical presentation of medically intractable MTLE consists of onset of habitual complex partial seizures during childhood, which may initially respond to antiepileptic drug (AED) therapy. The child does well for several years, but then complex partial seizures return in adolescence or early adulthood and are treatment resistant in at least one third (70). Usually there is a history of complex febrile seizures (71). There is an increased incidence of a family history of epilepsy and febrile seizures (72). The seizure characteristics include an aura in >90% of patients, with the most common being a rising epigastric sensation (51,73). The aura is followed by motor arrest and staring. Typical oroalimentary automatisms (i.e., lip smacking, chewing, swallowing) or fumbling, picking movements are characteristic. Unilateral dystonic posturing occurs contralateral to the side of onset. The duration of the seizure is usually between 30 and 90 s, with a postictal reorientation that may last several minutes. The seizure is followed by a postictal phase, which is longer if the event originated from the language-dominant side. The interictal EEG shows anterior temporal slowing and epileptiform discharges (Fig. 6A and B)(74,75). These are unilateral in most, but in ≤40% of patients, may occur bilaterally. When this occurs, they are preponderant over the side of seizure origin in half (74). Ictal EEG usually consists of unilateral, theta-frequency rhythmic sharp waves appearing within 30 s of the first ictal EEG abnormality (Figs. 7A–E and 8A and B)(74,76). High-resolution MRI demonstrates unilateral hippocampal atrophy with increased signal on T2-weighted and FLAIR images, seen best on oblique coronal views (Fig. 9). Other supportive studies are usually performed before epilepsy surgery (74,77,78). MTLE should be referred for surgical evaluation if two AEDs have failed to control the seizures. If surgery is performed, patients are relieved of disabling seizures before they interfere with critical social and vocational development during adolescence. This gives the best psychosocial outcome. If seizures continue through adolescence, even if they are abolished later in life by using surgical treatment, the patient may remain a psychosocial invalid. Early surgical intervention offers the greatest potential to restore an adolescent to a normal life. Most medically refractory epilepsy in childhood is extratemporal in origin. However, mesial temporal sclerosis and refractory temporal lobe epilepsy can present in childhood.


Figure 6. A, B: EEG in patient with right mesial temporal lobe epilepsy showing a characteristic unilateral interictal anterior temporal sharp wave.


Figure 7. A–E: Ictal EEG (consecutive tracings) in a patient with right mesial temporal lobe epilepsy shows evolution of right temporal rhythmic theta frequencies. These slow to delta frequencies and then abruptly stop (end of strips).


Figure 8. A, B: Ictal EEG (consecutive tracings) in a patient with right mesial temporal lobe epilepsy shows right mesial temporal (SP2) rhythmic theta frequency sharp waves at seizure onset.


Figure 9. A 15-year-old girl with left-sided hippocampal sclerosis. Angled coronal T2-weighted magnetic resonance imaging shows an area of increased signal intensity and hippocampal atrophy on the left side. (The left hippocampus is on the right side of the figure.)

Download figure to PowerPoint

Davidson and Falconer (79) reported the first series of children younger than 16 years with intractable partial seizures who underwent temporal lobectomy. More than half of the children had their epilepsy on the basis of MTLE. Falconer thought that temporal lobectomy in childhood gave better results than that in people two to three decades older. Mizrahi et al. (80) noted more frequent psychosocial, behavioral, and educational problems occurring in patients whose temporal lobectomy was delayed until adult life. Independently, Meyer et al. (81) noted similar improvements and also concluded that children with medically intractable MTLE should be offered early consideration of surgical intervention.

It is now established that mesial temporal sclerosis and medically refractory temporal lobe epilepsy may present in childhood (72,79,82). The youngest reported case is younger than 1 year. The clinical semiology of the seizure, interictal, and ictal EEG are all similar to that of adults with MTLE (72,82,83). In younger children, the automatisms may be simpler, typically limited to lip smacking and fumbling hand gestures. Often these children will have a history of prior febrile seizures, which may be prolonged or with focal features (79). Modern neuroimaging reveals the characteristic findings of hippocampal sclerosis on MRI (82,84).

Recently Gaillard et al. (85) reviewed their experience in identifying mesial temporal sclerosis with MRI in children and adolescents (85). They identified six children younger than 5 years and nine children between 5 and 10 years, suggesting that MTLE may be more common in young children than previously assumed. This finding collaborates prior work that evaluated 63 children with new-onset TLE and identified 13 with MRI evidence of hippocampal sclerosis (86). All but one had a history of a significant antecedent (i.e., focal or prolonged febrile seizure, meningitis). Seizure onset had a bimodal distribution, showing peaks in early (aged 0–3 years) and late childhood (aged 7–10 years). Hippocampal sclerosis is probably the most common lesion in children with intractable TLE, and hippocampal sclerosis may be underdiagnosed in children.

The safety and efficacy of surgery for medically refractory MTLE in children and adolescents is excellent, paralleling that observed in young adults.


  1. Top of page
  2. Abstract
  • 1
    Temkin O. The falling sickness. Baltimore: The John Hopkins University Press, 1945:143.
  • 2
    Penfield W, Jasper H. Epilepsy and the functional anatomy of the human brain. Boston: Little, Brown, 1954:562.
  • 3
    Bandler B, Kaufman C, Dykens JW, et al. Seizures and the menstrual cycle. Am J Psychiatry 1957;113:7048.
  • 4
    Diamantopoulos N, Crumrine PK. The effect of puberty on the course of epilepsy. Arch Neurol 1986;43:8736.
  • 5
    Rosciszewska D. The course of epilepsy at the age of puberty in girls. Neurol Neurochir Pol 1975;9:597602.
  • 6
    Logothetis J, Harner R, Morrell F, et al. The role of estrogen in catamenial exacerbation of epilepsy. Neurology 1959;9:35260.
  • 7
    Holmes GL, Donaldson JO. Effect of sexual hormones on the electroencephalogram and seizures. J Clin Neurophysiol 1987;4:122.
  • 8
    Vogel W, Broverman DM, Klaiber EL. Electroencephalographic responses in regularly menstruating women and in amenorrheic women treated with ovarian hormones. Science 1971;179:38891.
  • 9
    Tan M, Tan U. Effects of testosterone and clomiphene on spectral EEG and visual evoked response in a young man with post traumatic epilepsy. Int J Neurosci 2001;106:8794.
  • 10
    Backstrom T, Zetterlund B, Blom S, et al. Effects of intravenous progesterone infusions on the epileptic discharge frequency in women with partial epilepsy. Acta Neurol Scand 1984;67:2408.
  • 11
    Grunewald RA, Miberti V, Panayiotopoulos CP. Exacerbation of typical absence seizures by progesterone. Seizure 1992;1:1378.
  • 12
    Herzog AG. Psychoneuroendocrine aspects of temporolimbic epilepsy, Part I: brain, reproductive steroids and emotions. Psychosomatics 1999;40:95101.
  • 13
    Herzog AG. Psychoneuroendocrine aspects of temporolimbic epilepsy, Part III: case reports. Psychosomatics 1999;40:10916.
  • 14
    Logothetis J, Harner R. Electrocartical activation by estrogens. Arch Neurol 1960;3:2907.
  • 15
    Nicoletti F, Speciale C, Sortino MA, et al. Comparative effects of estradiol benzoate, the antiestrogen clomiphene citrate, and the progestin medroxyprogesterone acetate on kainic acid induced seizures in male and female rate. Epilepsia 1985;26:2527.
  • 16
    Sitt SL, Kinnard WJ. The effect of certain progestins and estrogens of the threshold of electrically induced seizure patterns. Neurology 1968;18:2136.
  • 17
    Wooley DE, Timiras PS, Rosenzweig MR, et al. Sex and strain differences in electroshock convulsions in the rat. Nature 1961;190:5156.
  • 18
    Woolley DE, Timiras PS, Rosenzweig MR, et al. Strain differences in seizure responses and brain cholinesterase activity in rats. Proc Soc Exp Biol Med 1963;112:7815.
  • 19
    Woolley CS. Estradiol facilitates kainic acid induced, but not flurothyl-induced, behavioral seizure activity in adult female rats. Epilepsia 2000;41:5105.
  • 20
    Luijtelaar G, Budziszewska B, Jaworska-Feil L, et al. The ovarian hormones and absence epilepsy: a long-term EEG study and pharmacological effects in a genetic absence epilepsy model. Epilepsy Res 2001;46:22539.
  • 21
    Delgado-Escueta AV, Medina MT, Serratosa JM, et al. Mapping and positional cloning of common idiopathic generalized epilepsies: juvenile myoclonic epilepsy and childhood absence epilepsy. In: OlsenRW, PorterRJ, eds. Jasper's basic mechanisms of the epilepsies. 3rd ed. (Adv Neurol, Vol. 79). Philadelphia: Lippincott Williams & Wilkins, 1999:35174.
  • 22
    Reutens DC, Berkovic SF. Idiopathic generalized epilepsy of adolescence: are the syndromes clinically distinct? Neurology 1995;45:146976.
  • 23
    Janz D. The idiopathic generalized epilepsies of adolescence with childhood and juvenile age of onset. Epilepsia 1997;38:411.
  • 24
    Wirrell EC, Camfield CS, Camfield PR, et al. Long-term prognosis of typical childhood absence epilepsy: remission or progression to juvenile myoclonic epilepsy. Neurology 1996;47:9128.
  • 25
    Andermann F, Berkovic SF. Idiopathic generalized epilepsy with generalized and other seizures in adolescence. Epilepsia 2001;42:31720.DOI: 10.1046/j.1528-1157.2001.36400.x
  • 26
    Greenberg DA, Durner M, Resor S, et al. The genetics of idiopathic generalized epilepsies of adolescent onset: differences between juvenile myoclonic epilepsy and epilepsy with random grand mal and with awakening grand mal. Neurology 1995;45:9426.
  • 27
    Moore T, Hecquet S, McLellann A, et al. Polymorphism analysis of JRK/JH8, the human homologue of mouse jerky and description of a rare mutation in a case of CAE evolving to JME. Epilepsy Res 2001;46:15767.
  • 28
    Donovan GP, Harden C, Gal J, Ho L, et al. Sensitivity of Jerky gene dosage underlies epileptic seizures in mice. J Neurosci 1997;17:45629.
  • 29
    Montalenti E, Imperiale D, Rovera A, et al. Clinical features, EEG findings and diagnostic pitfalls in juvenile myoclonic epilepsy: a series of 63 patients. J Neurol Sci 2001;184:6570.
  • 30
    Dhanuka AK, Jain BK, Daljit S, et al. Juvenile myoclonic epilepsy: a clinical and sleep EEG study. Seizure 2001;10:3748.
  • 31
    Delgado-Escueta AV, Enrile-Bacsal F. Juvenile myoclonic epilepsy of Janz. Neurology 1984;34:28594.
  • 32
    Janz D. Juvenile myoclonic epilepsy. Cleve Clin J Med 1989;56(suppl pt 1):S2333.
  • 33
    Genton P, Gelisse P. Juvenile myoclonic epilepsy. Arch Neurol 2001;58:148790.
  • 34
    Gardiner RM. Impact of our understanding of the genetic aetiology of epilepsy. J Neurol 2000;247:32734.
  • 35
    Liu AW, Delgado-Escueta AV, Serratosa JM, et al. Juvenile myoclonic epilepsy locus in chromosone 6p 21.2 – p11: linkage to convulsions and electroencephalography trait. Am J Hum Genet 1995;57:36881.
  • 36
    Greenberg DA, Durner M, Keddache M, et al. Reproducibility and complications in gene searches: linkage on chromosome 6, heterogeneity, association, and maternal inheritance in juvenile myoclonic epilepsy. Am J Hum Genet 2000;66:50816.
  • 37
    Elmslie FV, Rees M, Williamson WP, et al. Genetic mapping of a major susceptibility locus for juvenile myoclonic epilepsy on chromosome 15q. Hum Mol Genet 1997;6:132934.
  • 38
    Appleton RM, Beirne M, Acomb B. Photosensitivity in juvenile myoclonic epilepsy. Seizure 2000;9:10811.
  • 39
    Woermann FG, Free SL, Koepp MJ, et al. Abnormal cerebral structure in juvenile myoclonic epilepsy demonstrated with voxel-based analysis of MRI. Brain 1999;122:21017.
  • 40
    Lombroso CT. Consistent EEG focalities detected in subjects with primary generalized epilepsies monitored for two decades. Epilepsia 1997;38:797812.
  • 41
    Panayiotopoulos CP, Obeid T, Tahan AR. Juvenile myoclonic epilepsy: a 5-year prospective study. Epilepsia 1994;35:28596.
  • 42
    Gelisse P, Genton P, Rayboud C, et al. Structural brain lesions do not influence the prognosis of juvenile myoclonic epilepsy. Acta Neurol Scand 2000;102:18891.
  • 43
    Gelisse P, Genton P, Raybaud C, et al. Is it juvenile myoclonic epilepsy? Epileptic Disord 2000;2:2732.
  • 44
    Bauer J, Elger CE. Psychogenic seizures mimicking juvenile myoclonic epilepsy: case reports. Seizure 2001;10:20811.
  • 45
    Janz D. Epilepsy with grand mal on awakening and sleep-waking cycle. Clin Neurophysiol 2000;111(suppl 2):S10310.
  • 46
    Wolf P. Epilepsy with grand mal on awakening. In: RogerJ, BureauM, DravetC, et al., eds. Epileptic syndromes in infancy, childhood and adolescence. 2nd ed. London: John Libbey, 1992:32941.
  • 47
    Wolf P. Juvenile absence epilepsy. In: RogerJ, BureauM, DravetC, et al., eds. Epileptic syndromes in infancy, childhood and adolescence. 2nd ed. London: John Libbey, 1992:30712.
  • 48
    Berkovic SF, Andermann F, Andermann E, et al. Concepts of absence epilepsies: discrete syndromes or biological continuum? Neurology 1987;37:9931000.
  • 49
    Rodger J, Genton P, Bureau M, et al. Progressive myoclonus epilepsies in childhood and adolescence. In: RogerJ, BureauM, DravetC, et al., ed. Epileptic syndromes in infancy, childhood and adolescence. 2nd ed. London: John Libbey, 1992:381400.
  • 50
    Berkovic SF, Cochius J, Andermann E, et al. Progressive myoclonus epilepsies: clinical and genetic aspects. Epilepsia 1993;34(suppl 3):S1930.
  • 51
    Berkovic SF, So NK, Andermann F. Progressive myoclonus epilepsies: clinical and neurophysiological diagnosis. J Clin Neurophysiol 1991;8:26174.
  • 52
    Minassian BA. Lafora's disease: towards a clinical, pathologic, and molecular synthesis. Pediatr Neurol 2001;25:219.
  • 53
    So N, Berkovic SF, Andermann F, et al. Myoclonus epilepsy and ragged-red fibres (MERRF). Brain 1989;112:126176.
  • 54
    Wisniewski KE, Kida E, Connell F, et al. Neuronal ceroid lipofuscinoses: research update. Neurol Sci 2000;21(suppl 3):S4956.
  • 55
    Zong N, Wisniewski KE. Outlook for future treatment. Adv Genet 2001;45:21724.
  • 56
    Wisniewski KE, Kida E, Golgbek AA, et al. Neuronal ceroid lipofuscinoses: classification and diagnosis. Adv Genet 2001;45:134.
  • 57
    Kida E, Golabek AA, Wisniewski KE. Cellular pathology and pathogenic aspects of neuronal ceroid lipofuscinoses. Adv Genet 2001;45:3568.
  • 58
    Santavuori P, Lauronen L, Kirveskari E, et al. Neuronal ceroid lipofuscinoses in childhood. Neurol Sci 2000;21(suppl 3):S3541.
  • 59
    Gardiner RM. The molecular genetic basis of the neuronal ceroid lipofuscinoses. Neurol Sci 2000;21(suppl 3):S159.
  • 60
    Junaid MA, Pullarkat RK. Biochemistry of neuronal ceroid lipofuscinoses. Adv Genet 2001;45:93106.
  • 61
    Wisniewski KE, Zhong N, Philippart M. Pheno/genotypic correlations of neuronal ceroid lipofuscinoses. Neurology 2001;57:57681.
  • 62
    Donnet A, Habib M, Pellissier JF, et al. Kuf's disease presenting as progressive dementia with late onset generalized seizures: a clinicopathological and electrophysiological study. Epilepsia 1992;33:6474.
  • 63
    Goebel HH. The new nosography of the neuronal ceroid-lipofuscinoses. Ann Pathol 2000;20:47991.
  • 64
    Fuerst D, Shah J, Kupsky WJ, et al. Volumetric MRI, pathological, and neuropsychological progression in hippocampal sclerosis. Neurology 2001;57:1848.
  • 65
    Engel J. Mesial temporal lobe epilepsy: what have we learned? Neuroscientist 2001;7:34052.
  • 66
    Moser DJ, Bauer RM, Gilmore RL, et al. Electroencephalographic, volumetric, and neuropsychological indicators of seizure focus lateralization in temporal lobe epilepsy. Arch Neurol 2000;57:70712.
  • 67
    Cendes F, Li ML, Watson C, et al. Is ictal recording mandatory in temporal lobe epilepsy? Arch Neurol 2000;57:497500.
  • 68
    Pataraia E, Lurger S, Serles W, et al. Ictal scalp EEG in unilateral mesial temporal lobe epilepsy. Epilepsia 1998;39:60814.
  • 69
    Hogan RE. Mesial temporal sclerosis. Arch Neurol 2001;58:14846.
  • 70
    Currie S, Heathfiel KWG, Henson RA, et al. Clinical course and prognosis of temporal lobe epilepsy: a survey of 666 patients. Brain 1971;94:17390.
  • 71
    French JA, Williamson PD, Thadani NM. Characteristics of medial temporal lobe epilepsy. I: results of history and physical examination. Ann Neurol 1993;34:77480.
  • 72
    Bourgeois BFD. Temporal lobe epilepsy in infants and children. Brain Dev 1998;20:13541.
  • 73
    Quesney LF. Clinical and EEG features of complex partial seizures of temporal lobe origin. Epilepsia 1986;27(suppl 2):S2745.
  • 74
    Williamson PD, French JA, Thadani VM, et al. Characteristics of medial temporal lobe epilepsy, II: interictal and ictal scalp electroencephalography, neuropsychological testing, neuroimaging, surgical results and pathology. Ann Neurol 1993;34:7817.
  • 75
    Schulz R, Luders HO, Hoppe M, et al. Interictal EEG and ictal scalp EEG propagation are highly predictive of surgical outcome in mesial temporal lobe epilepsy. Epilepsia 2000;41:56470.
  • 76
    Ebner A, Hoppe M. Noninvasive electroencephalography and mesial temporal sclerosis. J Clin Neurophysiol 1995;12:2331.
  • 77
    Velasco AL, Wilson CL, Babb TL, et al. Functional and anatomic correlates of two frequently observed temporal lobe seizure-onset patterns. Neural Plasticity 2000;7:4963.
  • 78
    King D, Spencer S. Invasive electroencephalography in mesial temporal lobe epilepsy. J Clin Neurophysiol 1995;12:3245.
  • 79
    Davidson S, Falconer MA. Outcome of surgery in 40 children with temporal-lobe epilepsy. Lancet 1975;1:12603.
  • 80
    Mizrahi EM, Kellaway P, Grossman RG, et al. Anterior temporal lobectomy and medically refractory temporal lobe epilepsy of childhood. Epilepsia 1990;31:30212.
  • 81
    Meyer FB, Marsh R, Laws E, et al. Temporal lobectomy in children with epilepsy. J Neurosurg 1986;64:3716.
  • 82
    Salanova V, Markand O, Worth R, et al. Presurgical evaluation and surgical outcome of temporal lobe epilepsy. Pediatr Neurol 1999;20:17984.
  • 83
    Wyllie E, Chee M, Granstrom M-L, et al. Temporal lobe epilepsy in early childhood. Epilepsia 1993;34:85968.
  • 84
    Scott RC, Gadian DG, Cross JH, et al. Quantitative magnetic resonance characterization of mesial temporal sclerosis in childhood. Neurology 2001;56:165965.
  • 85
    Gaillard WD, Phulwani P, Dubovsky EC, et al. Mesial temporal sclerosis in children and adolescents. Epilepsia 1997;38(suppl 8):137.
  • 86
    Harvey AS, Berkovic SF, Wrennall JA, et al. Temporal lobe epilepsy in children: clinical, EEG and neuroimaging findings and syndrome classification in a cohort with new onset seizures. Neurology 1997;49:9608.